Literature DB >> 28350899

Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Jacqueline Huvane1, Lauren Komarow2, Carol Hill1, Thuy Tien T Tran2, Carol Pereira1, Susan L Rosenkranz3, Matt Finnemeyer2, Michelle Earley2, Hongyu Jeanne Jiang2, Rui Wang4,5, Judith Lok5, Scott R Evans2,5.   

Abstract

The Statistical and Data Management Center (SDMC) provides the Antibacterial Resistance Leadership Group (ARLG) with statistical and data management expertise to advance the ARLG research agenda. The SDMC is active at all stages of a study, including design; data collection and monitoring; data analyses and archival; and publication of study results. The SDMC enhances the scientific integrity of ARLG studies through the development and implementation of innovative and practical statistical methodologies and by educating research colleagues regarding the application of clinical trial fundamentals. This article summarizes the challenges and roles, as well as the innovative contributions in the design, monitoring, and analyses of clinical trials and diagnostic studies, of the ARLG SDMC.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibacterial resistance; data; innovation.; statistics

Mesh：

Substances：

Year:  2017        PMID： 28350899      PMCID： PMC5848245          DOI： 10.1093/cid/ciw827

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

1.  Editorial Commentary: A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs.

Authors:  Jose Molina; Jose M Cisneros
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

2.  Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.

Authors:  Claudia Manca; Carol Hill; Andrea M Hujer; Robin Patel; Scott R Evans; Robert A Bonomo; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 3.  The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.

Authors:  Deverick J Anderson; Timothy C Jenkins; Scott R Evans; Anthony D Harris; Robert A Weinstein; Pranita D Tamma; Jennifer H Han; Ritu Banerjee; Robin Patel; Theoklis Zaoutis; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

4.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

Review 5.  Methods and issues in studies of CRE.

Authors:  Scott R Evans; Anthony D Harris
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

6.  Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.

Authors:  Scott R Evans; Andrea M Hujer; Hongyu Jiang; Carol B Hill; Kristine M Hujer; Jose R Mediavilla; Claudia Manca; Thuy Tien T Tran; T Nicholas Domitrovic; Paul G Higgins; Harald Seifert; Barry N Kreiswirth; Robin Patel; Michael R Jacobs; Liang Chen; Rangarajan Sampath; Thomas Hall; Christine Marzan; Vance G Fowler; Henry F Chambers; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

7.  Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials.

Authors:  Lingling Li; Scott R Evans; Hajime Uno; L J Wei
Journal:  Stat Biopharm Res       Date:  2009-11-01       Impact factor: 1.452

8.  Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II.

Authors:  Scott R Evans; Andrea M Hujer; Hongyu Jiang; Kristine M Hujer; Thomas Hall; Christine Marzan; Michael R Jacobs; Rangarajan Sampath; David J Ecker; Claudia Manca; Kalyan Chavda; Pan Zhang; Helen Fernandez; Liang Chen; Jose R Mediavilla; Carol B Hill; Federico Perez; Angela M Caliendo; Vance G Fowler; Henry F Chambers; Barry N Kreiswirth; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2015-09-25       Impact factor: 9.079

9.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

10.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391
View more
  5 in total

Review 1.  Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.

Authors:  Ephraim L Tsalik; Elizabeth Petzold; Barry N Kreiswirth; Robert A Bonomo; Ritu Banerjee; Ebbing Lautenbach; Scott R Evans; Kimberly E Hanson; Jeffrey D Klausner; Robin Patel
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Authors:  Henry F Chip Chambers; Heather R Cross; Scott R Evans; Barry N Kreiswirth; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

3.  Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.

Authors:  Claudia Manca; Carol Hill; Andrea M Hujer; Robin Patel; Scott R Evans; Robert A Bonomo; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 4.  Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Sarah B Doernberg; Thomas P Lodise; Joshua T Thaden; Jose M Munita; Sara E Cosgrove; Cesar A Arias; Helen W Boucher; G Ralph Corey; Franklin D Lowy; Barbara Murray; Loren G Miller; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 5.  Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Yohei Doi; Robert A Bonomo; David C Hooper; Keith S Kaye; James R Johnson; Cornelius J Clancy; Joshua T Thaden; Martin E Stryjewski; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.